Antibody Industry Trends

On January 24, 2025, the novel monoclonal antibody Andembry (garadacimab) was approved in Australia! The drug is now approved for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 years and older with C1-esterase inhibitor deficiency or dysfunction. Andemb

B cells are central players in both humoral and cellular immunity, traditionally recognized for their role in antibody production. However, recent research highlights their direct involvement at sites of inflammation, where they establish tissue-resident memory populations and contribute to immune responses in infection, inflammatory diseases, and cancer.

​Inhaled antibody therapies represent a promising advancement in therapeutics, particularly for treating respiratory infections. By delivering antibodies directly to the lungs via inhalation, these therapies target pathogens at the primary site of infection, potentially improving efficacy and reducing systemic side effects.

Antibody therapeutics are emerging as a promising avenue in the fight against obesity, a condition that significantly elevates the risk of cardiovascular disease, type 2 diabetes, and certain cancers.

This morning, Helicore Biopharma emerged from stealth with $65M in Series A funding. They are focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists, with their most advanced asset, HCR-188, being a clinical stage monoclonal antibody (mAb) designed to bind GIP.

Biointron’s Q4 2024 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2024 (October, November, December).

Trispecific antibodies are an advanced class of engineered therapeutic proteins designed to simultaneously bind three distinct targets, offering enhanced precision and versatility in treating complex diseases, particularly cancer and immune-related disorders.

Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules designed to degrade specific proteins by recruiting an E3 ubiquitin ligase to the target protein, leading to its ubiquitylation and subsequent degradation by the proteasome. This novel mechanism enables PROTACs to eliminate on

According to Research and Markets, the global market for Fc and glycoengineered antibodies is projected to be worth US$38.8 billion in 2024. Over the next decade, the growth in opportunities for drug developers is expected to be driven by an increasing patient population and rising demand for these

Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected mosquitoes. Of the five species of Plasmodium that cause malaria, Plasmodium falciparum is the deadliest, responsible for the majority of cases and deaths, particularly in Africa, where young children are

This report aims to explore the events and trends of the biopharmaceutical industry in 2024 (YTD December 2024). This year, 22 novel antibody drugs have been approved by at least one regulatory agency around the world.

Alzheimer’s research has undergone transformative changes in recent years, characterized by breakthroughs, controversies, and a reevaluation of long-held theories. Recently, BioArctic announced a global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-